Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688091 Shanghai Yizhong Pharmaceutical
73.250
+3.840+5.53%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Per Share Indicator
Net Asset Per Share
10.38% 12.0955 300.98% 11.6873 280.13% 11.4016 262.06% 11.111
Basic Earning Per Share
508.33% 0.98 486.67% 0.58 514.29% 0.29 82.14% -0.05
Diluted  Earning Per Share
508.33% 0.98 486.67% 0.58 514.29% 0.29 82.14% -0.05
Earning Per Share
617.67% 0.9846 474.04% 0.5764 518.73% 0.2906 86.27% -0.0378
Diluted Earning Per Share(TTM)
540.87% 1.137 315.02% 0.6541 210.72% 0.3048 86.27% -0.0378
Capital Surplus Funds Per Share
0.00% 10.362 340.36% 10.362 -- 10.362 340.36% 10.362
Undivided Profit Per Share
281.78% 0.7335 174.20% 0.3253 -- 0.0395 11.74% -0.251
Operating Cash Flow Per Share
339.72% 0.9373 165.28% 0.2755 190.00% 0.2007 -81.04% -0.4611
Enterprise FCF Per Share
261.74% 5.3553 2,362.53% 5.0545 193.98% 1.544 -1,168.74% -7.945
Shareholder FCF Per Share
249.79% 5.1969 1,226.86% 4.8962 317.16% 1.4029 -1,257.86% -8.134
EBIT Per Share
493.08% 0.8695 385.42% 0.5109 428.03% 0.2703 53.06% -0.1427
Profitability
ROE Weighted
245.63% 8.490% 198.25% 5.060% -- 2.580% 90.22% -0.840%
ROE
568.97% 8.140% 193.29% 4.932% 210.20% 2.549% 96.21% -0.340%
ROA
397.38% 8.233% 205.72% 4.977% 221.21% 2.544% 93.27% -0.548%
ROIC
326.79% 7.443% 178.05% 4.451% 193.36% 2.383% 77.73% -2.098%
Net Profit Ratio
-- 62.629% -- 84.846% -- 89.524% -- -98.026%
Gross Income Ratio
-- 92.910% -- 92.300% -- 93.251% -- 92.746%
EBIT To Total Operating Revenue
-- 55.308% -- 75.210% -- 83.271% -- -370.219%
Period Costs Rate
-- 35.820% -- 17.053% -- 21.017% -- 606.559%
Operating Expense Rate
-- 35.759% -- 15.880% -- 13.899% -- 56.846%
Admini Expense Rate
-- 3.975% -- 5.944% -- 6.473% -- 367.238%
Financial Expense Rate
-- -6.769% -- -8.302% -- -3.596% -- -142.226%
Recurrent Net Profit
429.88% 81.97M 409.76% 46.79M -- 23.12M 41.01% -17.73M
Operating Profit Ratio
-- 62.930% -- 84.525% -- 86.867% -- -227.624%
EBIT
493.10% 91.99M 480.62% 54.05M 537.22% 28.6M 37.41% -15.1M
Solvency
Current Ratio
-24.29% 23.4785 4,030.11% 97.9455 -- 133.0897 838.80% 47.079
Quick Ratio
-24.51% 23.1539 4,027.05% 96.0612 -- 130.9983 852.02% 46.5207
Debt Equity Ratio
27.81% 3.911% -91.39% 1.092% -92.44% 0.883% -66.13% 2.129%
Shareholders Equity Without Minority Interests To Total Liabilities
-21.76% 2556.706% 1,061.45% 9153.934% 1,221.90% 11320.583% 195.26% 4697.998%
Shareholders Equity Without Minority Interests To Interest Bear Debt
-- -- -- -- 7,639.41% 66.28K% -6.33% 7.02K%
Long Debt To Working Capital
-25.71% 0.0026 -97.21% 0.0028 -- 0.0029 -95.13% 0.004
Growth Ability
Sustainable Grow Rate
-- 8.861% -- 5.187% -- 2.615% -- --
Operating Capacity
Operating Cycle(D/T)
-- 341.7845 -- 561.8872 -- 569.3816 -- 8.43K
Inventory Turnover Days(D/T)
-- 310.5233 -- 516.203 -- 540.8654 -- 8.07K
Accounts Receivable Turnover Days(D/T)
-- 31.2612 -- 45.6841 -- 28.5162 -- 362.4283
Inventory turnover Rate(T)
-- 0.8696 -- 0.3487 -- 0.1664 -- 0.0446
Accounts Receivable Turnover Rate(T)
-- 8.6369 -- 3.9402 -- 3.1561 -- 0.9934
Current Assets Turnover Rate(T)
-- 0.1582 -- 0.0708 -- 0.0341 -- 0.0078
Total Assets Turnover Rate(T)
-- 0.1315 -- 0.0587 -- 0.0284 -- 0.0056
Fixed Assets Turnover Rate(T)
-- 2.0512 -- 0.8784 -- 0.4175 -- 0.0481
Equity Turnover Rate(T)
-- 0.1355 -- 0.0596 -- 0.0288 -- 0.0057
Cash Position
Free Cash Flow
261.74% 566.59M 3,116.07% 534.77M 291.99% 163.36M -1,524.95% -840.58M
Net Profit Cash Cover
-- 95.199% -- 47.797% -- 69.061% -- --
Operating Revenue Cash Cover
-- 86.217% -- 62.089% -- 69.718% -- 9.820%
Operating Cash In To Assets
237.72% 7.838% 118.45% 2.379% 126.04% 1.757% 11.28% -6.686%
Dividend Ability
Dividend Paid Ratio
-- 0.000% -- 0.000% -- 0.000% -- --
Retained Earning Ratio
-- 100.000% -- 100.000% -- 100.000% -- --
Capital Structure
Debt Assets Ratio
26.76% 3.764% -90.40% 1.081% -91.63% 0.876% -64.75% 2.084%
Current Assets To Total Assets
0.05% 83.453% 253.62% 82.978% -- 84.028% 271.03% 82.757%
Non Current Assets To Total Assets
-0.27% 16.547% -77.76% 17.022% -- 15.973% -77.81% 17.243%
Fix Assets Ratio
-14.11% 6.002% -80.08% 6.502% -- 6.751% -79.65% 6.861%
Interest Bearing Debt To Total Capital
-- 0.000% -- 0.000% -98.56% 0.151% 6.67% 1.405%
Yield Quality
Net Income From Value Changes To Total Profit
-- 10.356% -- 13.211% -- 18.519% -- --
Recurrent Net Profit To Net Profit
-- 78.690% -- 76.734% -- 75.206% -- --
Dupont Analysis
Equity Multipler_DuPont
-0.54% 103.058% -7.14% 101.597% -6.84% 101.498% -2.44% 102.842%
Net Profit of Parent Company OwnersTo Net Profit_DuPont
0.00% 100.000% 0.00% 100.000% 0.00% 100.000% 0.00% 100.000%
Net Profit To Total Operating Revenue_DuPont
-- 62.629% -- 84.846% -- 89.524% -- -98.026%
Net Profit To Total Profit_DuPont
-- 100.889% -- 101.589% -- 103.059% -- --
Total Profit To EBIT_DuPont
-- 112.240% -- 111.048% -- 104.318% -- --
EBIT To Total Operating Revenue_DuPont
-- 55.308% -- 75.210% -- 83.271% -- -370.219%
Currency Unit
CNYCNYCNYCNY

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is committed to the development of new dosage forms of antineoplastic drugs and related products. The company is committed to the R & D and industrialization of improved new drugs for antineoplastic drugs, with high-tech talents with the background of polymer materials, pharmaceutical preparations and biology, and mastering the core and key technologies for the synthesis of nano-drug carriers and medicinal polymer excipients. The company's main research and development product is paclitaxel micelles. Paclitaxel micelle is an innovative lyophilized powder injection without polyoxyethylene castor oil and methoxy polyethylene glycol 2000-poly (lactide) copolymer as carrier.
CEO: Jingsong Zhou
Market: --
Listing Date: 09/09/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist